Centrally mediated hyperglycemia by 6-aminonicotinamide.
Some metabolic changes induced by the intraventricular administration of 6-aminonicotinamide (6-AN) were studied in mice. Five or ten microgram/animal of 6-AN produced a marked hyperglycemia, lowered glycogen content in the brain and liver, and reduced the adrenal epinephrine content. Adrenalectomy or hexamethonium prevented 6-AN-induced hyperglycemia and decrease of glycogen content in the liver but not in the brain. Decrease of adrenal epinephrine content induced by 6-AN was overcome by hexamethonium. Pretreatment with 6-AN (10 microgram/animal) markedly lowered the toxic action, but not the hypoglycemic action, of a large dose of insulin.
D015120:6-Aminonicotinamide / Q000494:pharmacology*; D000315:Adrenalectomy; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D006003:Glycogen / Q000378:metabolism; D006943:Hyperglycemia / Q000139:chemically induced / Q000378:metabolism*; D007003:Hypoglycemia / Q000378:metabolism; D007328:Insulin / Q000633:toxicity; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008112:Liver Glycogen / Q000378:metabolism; D008297:Male; D051379:Mice; D009536:Niacinamide / Q000031:analogs & derivatives*
D001786:Blood Glucose; D007328:Insulin; D008112:Liver Glycogen; D009536:Niacinamide; D015120:6-Aminonicotinamide; D006003:Glycogen